0.00Open0.10Pre Close0 Volume2 Open Interest25.00Strike Price0.00Turnover0.00%IV126.13%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma111.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Wave Life Sciences Stock Discussion
Back to 16 next week
Wave Life Sciences Announces First-Ever Therapeutic Rna Editing in Humans Achieved in Restoraation-2 Trial of Wve-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd: Expects to Share Multidose Data From Restoraation-2 Trial in 2025
No comment yet